The End of Painstaking Ex Vivo Manufacturing

Conventional CAR-T cell therapy historically required collecting patient blood, transporting cells to specialized biomanufacturing cleanrooms, genetically modifying them over several weeks, and reinfusing them following toxic lymphodepletion chemotherapy.

The JY231 formulation encapsulates genetic editing payloads inside lipid nanoparticles engineered to dock exclusively onto endogenous T-cells in vivo, converting the patient's own vascular system into an active therapeutic bioreactor.